CIPF / Nuevos Fármacos / Bioinformática Descubrimiento de dianas terapéuticas para enfermedades tropicales



http://sgu.bioinfo.cipf.es

Structural Genomics Unit Bioinformatics Department Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain



Data in the post-genomic era

Progress in science depends on new techniques, new discoveries and new ideas, probably in that order.

Sydney Brenner, 1980



The introduction and popularization of high-throughput techniques has drastically changed the way in which biological problems can be addressed and hypotheses can be tested.

But not necessarily the way in which we really address or test them...



Genes in the DNA...

...code for proteins...

...produces the final phenotype

>protein kunase acctgttgatggcgacagggactgtatgctg atctatgctgatgcatgcatgctgactactgat

From genotype to phenotype.

...whose structure accounts

...plus the environment...



Now: 22240 (NCBI build 35 12/04) 50-70% display alternative splicing 25%-60% unknown >protein kunase **Transfrags** acctgttgatggcgacagggactgtatgctgatctat



...which can be different because of the variability. ^{10 million SNPs}



...whose final ffect configures the phenotype...

...when expressed in the proper moment and place...

A typical tissue is expressing among 5000 and 10000 genes



gctgatgcatgcatgctgactactgatgtgggggcta

tgacttgatgtctatc

From genotype to phenotype.

(post-genomics scenario)



...conforming complex interaction networks...

...code for proteins.

That undergo posttranslational modifications. somatic recombination...

100K-500K proteins

...whose structures account for function...



... in cooperation with other proteins...

Each protein has an average of 8 interactions

"The Aim"

Extracting as much information as possible from/for one single data



Bioinformatics Department http://bioinfo.cipf.es



Bioinformatics Department <u>http://bioinfo.cipf.es</u>



Functional Genomics Dr. Joaquín Dopazo



B^ABELOMICS

http://gepas.bioinfo.cipf.es Gene Expression Pattern Analysis Suite

> http://pupasuite.bioinfo.cipf.es SNP Analysis Suite

http://babelomics.bioinfo.cipf.es Functional Profiling Analysis Suite



Comparative Genomics Pharmacogenomics Dr. Hernán Dopazo



http://phylemon.bioinfo.cipf.es Molecular Evolution Analysis Suite



Structural Genomics Dr. Marc A. Marti-Renom



http://www.dbali.org Structural Biology Analysis Suite

Bioinformatics Department <u>http://bioinfo.cipf.es</u>





Tropical Disease Initiative (TDI)

Predicting binding sites in protein structure models.



http://www.tropicaldisease.org

Need is High in the Tail

DALY Burden Per Disease in Developed CountriesDALY Burden Per Disease in Developing Countries



Disease data taken from WHO, <u>World Health Report 2004</u> DALY - Disability adjusted life years

DALY is not a perfect measure of market size, but is certainly a good measure for importance.

DALYs for a disease are the sum of the years of life lost due to premature mortality (YLL) in the population and the years lost due to disability (YLD) for incident cases of the health condition. The DALY is a health gap measure that extends the concept of potential years of life lost due to premature death (PYLL) to include equivalent years of 'healthy' life lost in states of less than full health, broadly termed disability. One DALY represents the loss of one year of equivalent full health.

Need is High in the Tail

DALY Burden Per Disease in Developed CountriesDALY Burden Per Disease in Developing Countries



Disease data taken from WHO, <u>World Health Report 2004</u> DALY - Disability adjusted life years market size, but is certainly a good measure for importance.

DALY is not a perfect measure of market size, but is certainly a good measure for importance.

DALYs for a disease are the sum of the years of life lost due to premature mortality (YLL) in the population and the years lost due to disability (YLD) for incident cases of the health condition. The DALY is a health gap measure that extends the concept of potential years of life lost due to premature death (PYLL) to include equivalent years of 'healthy' life lost in states of less than full health, broadly termed disability. One DALY represents the loss of one year of equivalent full health.

Modeling Genomes

data from models generated by ModPipe (Eswar, Pieper & Sali)



A good model has MPQS of 1.1 or higher

Comparative docking

2. Inheritance

1. Expansion



Summary table

models with inherited ligands

from 16,284 good models, 295 inherited a ligand/substance with at least one compound already approved by FDA and ready to be used from ZINC

	Transcripts	Good	Ligands	Lipinski	Lipinski+ZINC	FDA+ZINC
C. hominis	3,886	886	183	131	28	12 (10)
C. parvum	3,806	949	219	145	30	12 (10)
L. major	8,274	1,845	488	334	84	44 (34)
M. leprae	١,605	1,321	286	189	39	29 (25)
M. tuberculosis	3,991	2,887	404	285	71	44 (37)
P. falciparum	5,363	1,057	271	191	48	20 (16)
P. vivax	5,342	1,042	267	177	37	18 (15)
T. brucei	921	1,795	440	309	94	46 (36)
T. cruzi	19,607	3,915	730	493	127	62 (52)
T. gondii	7,793	587	174	124	28	8 (7)
TOTAL	60,588	16,284	3,462	2,378	586	295 (242)

Example of inheritance (inheritance)

LmjF21.0680 from L. major "Histone deacetylase 2" (model 1)

	Formula	Name	Cov.	Seq, Id. (%)	Residues
TSN	C ₁₇ H ₂₂ N ₂ O ₃	Trichostatin A	100.00	90.9	90 131 132 140 141 167
SHH	C ₁₄ H ₂₀ N ₂ O ₃	Octadenioic acid hudroxyamide phenylamide	100.00	90.9	169 256 263 293 29



Example of inheritance (CDD-Roos-literature)

LmjF21.0680 from L. major "Histone deacetylase 2" (model 1)

Proc. Natl. Acad. Sci. USA Vol. 93, pp. 13143–13147, November 1996 Medical Sciences

Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase

(cyclic tetrapeptide/Apicomplexa/antiparasitic/malaria/coccidiosis)

Sandra J. Darkin-Rattray^{*†}, Anne M. Gurnett^{*}, Robert W. Myers^{*}, Paula M. Dulski^{*}, Tami M. Crumley^{*}, John J. Allocco^{*}, Christine Cannova^{*}, Peter T. Meinke[‡], Steven L. Colletti[‡], Maria A. Bednarek[‡], Sheo B. Singh[§], Michael A. Goetz[§], Anne W. Dombrowski[§], Jon D. Polishook[§], and Dennis M. Schmatz^{*}

Departments of *Parasite Biochemistry and Cell Biology, [‡]Medicinal Chemistry, and [§]Natural Products Drug Discovery, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2004, p. 1435–1436 0066-4804/04/\$08.00+0 DOI: 10.1128/AAC.48.4.1435–1436.2004 Copyright © 2004, American Society for Microbiology. All Rights Reserved. Vol. 48, No. 4

Antimalarial and Antileishmanial Activities of Aroyl-Pyrrolyl-Hydroxyamides, a New Class of Histone Deacetylase Inhibitors



Acknowledgments

Structural Genomics Unit (CIPF) Marc A. Marti-Renom Emidio Capriotti Peio Ziarsolo Areitioaurtena

Comparative Genomics Unit (CIPF) Hernán Dopazo Leo Arbiza Francisco García

Functional Genomics Unit (CIPF)

Joaquín Dopazo Fátima Al-Shahrour José Carbonell Ignacio Medina David Montaner Joaquin Tárraga Ana Conesa Toni Gabaldón Eva Alloza Lucía Conde Stefan Goetz Jaime Huerta Cepas Marina Marcet Pablo Minguez Jordi Burguet Castell

FUNDING

Prince Felipe Research Center Marie Curie Reintegration Grant STREP EU Grant Generalitat Valenciana Tropical Disease Initiative Stephen Maurer (UC Berkeley) Arti Rai (Duke U) Andrej Sali (UCSF) Ginger Taylor (TSL) Barri Bunin (CDD)

STRUCTURAL GENOMICS

Stephen Burley (SGX) John Kuriyan (UCB) **NY-SGXRC**

MAMMOTH Angel R. Ortiz

BIOLOGY

Jeff Friedman (RU) James Hudsped (RU) Partho Ghosh (UCSD) **Alvaro Monteiro (Cornell U)** Stephen Krilis (St.George H)

FUNCTIONAL ANNOTATION Fatima AI-Shahrour Joaquin Dopazo COMPARATIVE MODELING Andrej Sali M. S. Madhusudhan Narayanan Eswar Min-Yi Shen Ursula Pieper Bino John Maya Topf

FUNCTIONAL ANNOTATION Andrea Rossi Fred Davis



http://bioinfo.cipf.es
http://sgu.bioinfo.cipf.es